Dual-target CD19/BCMA-CAR-T strategies, which have been predominantly tested in SLE and LN patients, synergistically eliminate B cells and plasma cells, suppressing anti-dsDNA and anti-Ro antibodies. The gene discussed is CD19; the disease is systemic lupus erythematosus.